GLP-1 Beyond Weight Loss: What’s Proven and What’s Hype

GLP-1 drugs have outgrown the weight-loss label

Oral semaglutide now makes the pitch simpler: no injector pen, no needle, no weekly ritual in the fridge. In the OASIS 4 phase 3 trial, adults with overweight or obesity taking oral semaglutide 25 mg lost a mean 13.6% of body weight at 64 weeks versus placebo, alongside improvements in blood pressure, cholesterol, blood sugar, and inflammation. That result helped support the FDA's December 2025 approval of oral semaglutide 25 mg for weight management.

The practical appeal is obvious. What matters more is what happened after GLP-1 drugs left the obesity clinic and started showing up in cardiology, pulmonology, and neurology journals. Some of that expansion is real medicine. Some of it is an evidence gap wearing a very expensive suit.

The cleanest way to read this field is by tier: what is proven now, what looks promising but still rests on weaker evidence, and what remains a biologically interesting maybe.

What is ready now: weight loss and cardiovascular disease

The weight-loss effect is no longer controversial. Randomized trials of semaglutide and related drugs consistently land in the rough range of 10% to 15% body-weight reduction under controlled conditions. Oral semaglutide now joins the injectable class with phase 3 evidence, which matters because convenience changes adherence. A drug cannot work if it sits in the cabinet judging you.

Real-world performance is less dramatic. Two observational studies of oral semaglutide in obesity, one in Medicina Clínica and another independent retrospective analysis in Frontiers in Endocrinology, support meaningful weight and metabolic benefits outside trial conditions. But routine practice usually trails the headlines. An AJMC summary of published real-world data points to lower weight loss in practice, largely because titration stalls, side effects push people off target doses, and adherence falls without the structure of a trial. If a trial says 13.6%, a real clinic should expect less.

The cardiovascular case is stronger than the weight-loss story, not weaker. A 2026 secondary analysis of the SOUL randomized clinical trial found that oral semaglutide 14 mg reduced heart failure events by 22% in people with type 2 diabetes who already had a history of heart failure. The same analysis reported lower major cardiovascular event risk regardless of heart-failure status. That finding matters because it pushes GLP-1 drugs beyond the lazy theory that they help only by making people lighter.

That broader cardiovascular signal did not come out of nowhere. The research concept here also points to SELECT in people with obesity without diabetes and STEP-HFpEF in heart failure with preserved ejection fraction, where semaglutide improved symptoms in a condition with very few useful options. A separate real-world federated network analysis in ESC Heart Failure suggests tirzepatide may outperform semaglutide in some patients with obesity and HFpEF, though that comparison is observational and should not be mistaken for a head-to-head randomized verdict.

Next-generation oral drugs may sharpen this point. A 2025 meta-analysis of orforglipron found more than 10% weight loss across 26 to 72 weeks and reported that blood pressure, LDL cholesterol, and triglyceride benefits plateaued at 12 to 24 mg doses, lower than the doses needed for maximal weight loss. Biomarker changes are not patient outcomes, and a biomarker plateau is not mechanistic proof. Still, the pattern supports the idea that at least some cardiovascular benefit is partly independent of appetite suppression and fat loss.

The respiratory story is plausible, but not settled

This is where the hype risk goes up. The biologic rationale is decent. A 2025 respiratory review notes GLP-1 receptor expression on airway epithelial and smooth-muscle cells and summarizes pathways that could affect inflammation and airway tone directly. Observational studies also point in the same direction.

A 10-year retrospective cohort study in Scientific Reports used the TriNetX U.S. electronic health record network to compare GLP-1 receptor agonist users with people on other antihyperglycemic drugs and found lower rates of respiratory complications including pulmonary fibrosis signals over follow-up. The broader respiratory review also summarizes fewer COPD exacerbations and fewer asthma hospitalizations in observational datasets.

Then there is sleep apnea, where the evidence is better. A 2025 randomized trial analysis from SURMOUNT-OSA found that tirzepatide reduced obstructive sleep apnea severity and improved cardiometabolic risk markers over 52 weeks in an obese population. That is randomized evidence tied to a respiratory or sleep-related outcome, and it should be taken seriously.

But the field still lacks the one thing that would settle the bigger question: a completed randomized trial with a primary respiratory endpoint in diseases such as COPD or asthma. According to the evidence summarized here, that trial does not yet exist. Without it, the clean alternative explanation remains on the table: people breathe better when they weigh less, sleep better, and have less metabolic stress. That is a useful effect either way. It is not the same as proving a direct lung treatment.

The brain story is fascinating, and still early

The neurology data are the most provocative and the easiest to overclaim. A 2024 propensity-matched cohort study reported that GLP-1 receptor agonist use was associated with a 36% to 60% lower risk of Parkinson's disease compared with other diabetes medications in patients with type 2 diabetes or obesity. If a randomized prevention trial ever reproduces even the lower end of that range, the field changes overnight.

There is also a coherent preclinical rationale. A 2025 review in the Journal of Clinical Investigation describes evidence that GLP-1 drugs can reduce neuroinflammation, improve mitochondrial function, support proteostasis, and limit toxic protein buildup in animal and translational models, including amyloid, tau, and alpha-synuclein pathways. Those mechanisms fit major theories of Alzheimer's and Parkinson's disease.

What they do not yet fit is a clean human treatment recommendation. The same JCI review says clinical trial results so far are mixed. Current molecules may not reach the central nervous system well enough. Researchers still do not know the best disease stage to target, which patients are most likely to benefit, or whether the observational signal reflects biology, healthier patients getting newer drugs, or both. A large relative association is still an association.

The catch: good drugs can still have real limits

The strongest GLP-1 outcome trials remain heavily tied to manufacturer sponsorship, especially Novo Nordisk. That does not nullify the results, but it increases the need for independent replication. A 2024 Nature Medicine risk-mapping study and a 2025 review in Cardiovascular Diabetology add the missing friction: gastrointestinal adverse effects, pancreatitis signals, discontinuation problems, cost barriers, and the blunt fact that cardiometabolic gains often fade after stopping treatment.

Body composition also matters. These drugs reduce lean mass along with fat mass, which may be a manageable tradeoff in some adults and a serious problem in older patients who already have little muscle reserve. The boxed warning about thyroid C-cell tumors remains based on rodent data rather than confirmed human harm, but it remains on the label. Trial populations also skew toward people with better access, closer follow-up, and more support than the average patient gets.

Verdict: GLP-1 agonists already count as one of the most important cardiometabolic drug classes in current practice. The evidence for weight loss and cardiovascular benefit is strong enough to act on now. The respiratory and neuroprotection stories are real research programs, not fantasy. They are not finished clinical arguments.

That distinction matters because this class has reached the point where both believers and skeptics can get lazy. The believers flatten every promising signal into a treatment revolution. The skeptics keep talking as if these are merely appetite suppressants with good branding. Neither view survives contact with the data.

Right now, the most defensible position is straightforward. Oral semaglutide gives the field a practical new delivery format backed by phase 3 weight-loss evidence. Cardiovascular benefit appears to extend beyond the scale, with randomized support in high-risk patients with type 2 diabetes and heart failure. Respiratory benefit looks plausible but remains mostly observational outside sleep apnea. Neuroprotection has strong mechanistic logic and striking cohort data, but human proof is incomplete.

That is enough to take GLP-1 drugs seriously as more than weight-loss medications. It is not enough to pretend every organ system has already been won.